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Background: The A risk allele of rs9939609 of the fat mass- and obesity-associated gene (FTO) increases body fat mass.
Objective: To examine whether FTO rs9939609 affects obese individuals’ response to a high-fat, low-carbohydrate (CHO) (HF) or
low-fat, high-CHO (LF), hypo-energetic diet and whether the effect of the FTO variant depends on dietary fat and CHO content.
Design: In a 10-week, European, multi-centre dietary intervention study 771 obese women and men were randomized to either
LF (20–25% of energy (%E) from fat, 60–65%E from CHO) or HF (40–45%E from fat, 40–45%E from CHO), hypo-energetic diet
(measured resting metabolic rate multiplied by 1.3–600 kcal day1). Body weight, fat mass (FM), fat-free mass (FFM), waist
circumference (WC), resting energy expenditure (REE), fasting fat oxidation as % of REE (FatOx), insulin release (HOMA-b) and a
surrogate measure of insulin resistance (HOMA-IR) were measured at baseline and after the intervention. In all, 764 individuals
were genotyped for FTO rs9939609.
Results: For A-allele carriers the drop-out rate was higher on HF than LF diet (in AT, P¼0.002; in AT/AA combined, P¼0.003).
Among those individuals completing the intervention, we found no effect of FTO rs9939609 genotype on Dweight, DFM, DFFM,
DWC or DFatOx. However, participants with TT had a smaller reduction in REE on LF than on HF diet (75 kcal/24 h; interaction:
P¼0.0055). These individuals also showed the greatest reduction in HOMA-b and HOMA-IR (interaction: P¼0.0083 and
P¼0.047).
Conclusion: The FTO rs9939609 may interact with the macronutrient composition in weight loss diets in various ways; carriers
of the A allele on LF diet appear to have a lower risk for drop out, and TT individuals have a smaller decrease in REE and greater
decrease in HOMA-b and HOMA-IR on LF than on HF diet.
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Introduction
Genome-wide association studies discovered an obesity locus
in a highly conserved region of strong linkage disequilibrium
in the fat mass and obesity-associated gene (FTO).1–4
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The role of FTO variants as predisposing to obesity in
Caucasian populations is now established more firmly.5–8
The association to general fatness irrespective of its distribu-
tion is confirmed throughout the range of fatness9 and the
association between FTO variants and obesity is also seen in
Japanese people.10 In search for the mechanism by which
allelic variation in FTO affect adiposity, both central11 and
peripheral12,13 mechanisms have been examined. Several
studies indicate that FTO variants are associated with
appetite14 and energy intake,15,16 whereas energy expendi-
ture is unaffected.15–17
Although it is possible that the observed associations
between FTO single nucleotide polymorphisms (SNP)s and
obesity are caused by KIAA1005 located 200bp upstream of
the 50 end of FTO,1 it is a natural assumption that effects of
SNPs in FTO on obesity are mediated through the effects of
FTO itself. Studies in rodents provide evidence supporting a
central role for Fto in the regulation of energy balance.18–20
These studies suggest that FtoFlike the majority of genetic
defects associated with obesityFhas its principal impact on
the function of the hypothalamus, although the results are
inconsistent. In a 48-h deprivation model performed in mice
Fto mRNA levels in arcuate nucleusFwhich is of critical
importance for the control of energy balanceFwere reduced
by B60% in fasted compared with freely feeding mice. A
similar effect of starvation on hypothalamic Fto expression
was seen in another mouse study,20 whereas the opposite
effect was found in rats.18
It is of potential importance to identify individuals with a
genetic pattern that influences the response to weight
reduction therapy, but it is still unclear if variants in FTO
affect weight loss in obese individuals. Two studies are
published with findings of no association between FTO
variants (rs8050136 and rs9939609, respectively) and weight
loss.21,22 Further, it is unknown whether factors, such as
macronutrient composition, affect the association between
variants in FTO and weight loss. Previously 42 SNPs in 26
candidate genes for obesity (not including FTO) were
examined in relation to weight loss in the NUGENOB study
(Nutrient–gene interaction in human obesity: implication
for dietary guidelines), in which average weight loss was
6.8 kg after 10 weeks.23 The results suggested that the 42
SNPs under study did not have any major impact on weight
reduction during short-term either high-fat (HF) or low-fat
(LF) hypo-energetic diet in obese individuals. In this context
we decided to investigate the effect of FTO rs9939609
on diet-induced weight loss and associated phenotypes
including possible interactions with macronutrient content
of the weight loss diet in the NUGENOB-cohort.
Methods
The NUGENOB study was a randomized, parallel, two-arm,
open label, 10-week dietary intervention (trial registration:
ISRCTN25867281) of two hypo-energetic diets with
either low (LF) or high fat content (HF). NUGENOB
was a multi-centre study including eight clinical centres in
seven European countries (Sweden, Denmark, UK, The
Netherlands, Czech Republic, France (two clinical centres),
and Spain) and has been described in detail elsewhere
(www.nugenob.org).23,24
Participants were recruited from May 2001 until September
2002 through the media, from waiting lists or ongoing
population studies and by self-referral or referral from a
general practitioner or other clinical units and local obesity
organizations. Inclusion criteria were: body mass index (BMI;
kgm2) X30, and age 20–50 years. Exclusion criteria were:
weight change43 kg within 3 months before the start of the
study; hypertension, diabetes or hyperlipidemia treated by
drugs; untreated thyroid disease; surgically or drug-treated
obesity; pregnancy; participation in other trials and alcohol
or drug abuse.
The target macronutrient composition of the two diets
was: LF diet: 20–25% of total energy from fat, 15% from
protein and 60–65% from carbohydrate; HF diet: 40–45% of
total energy from fat, 15% from protein and 40–45% from
carbohydrate. Both diets were designed to provide
600 kcal day1 (2510 kJ day1) less than the individually
estimated daily energy requirement based on measured
initial resting metabolic rate multiplied by 1.3. Participants
were given oral and written instructions relating to these
targets based on either a template (see details at www.nu-
genob.org) or exchange system.25 Instructions were also
given to minimize differences between the two diets in other
components such as sources and type of fat, amount
and type of fibre, type of carbohydrate, fruit and vegetables
and meal frequency and participants were requested to
abstain from alcohol consumption. Dietary instructions were
reinforced weekly.
Seven hundred and seventy-one obese white Europeans
(579 women) were included and randomized to one of the
two intervention diets by stratified block randomization.
The randomization list was computer generated at the
coordinating centre and the block size was unknown to the
clinical centres. Informed written consent was obtained
before study participation and the study was approved by the
Ethical Committee at each participating centres.
Phenotypes
Before randomization to the weight loss intervention and after
completion of the intervention, participants underwent a
clinical investigation protocol starting at 0800h after a 12h
overnight fast. The first clinical investigation was preceded by
a 3-day dietary run in the period during which participants
had to keep to their habitual diet, avoid excessive physical
activity and alcohol consumption. The second clinical
investigation was conducted in the tenth week after start of
the dietary weight loss intervention programme.
Anthropometrics and body composition were assessed
after the participants voided the bladder. Body weight was
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measured on calibrated scales. Waist circumference (WC)
was measured with the participant wearing only non-
restrictive underwear. Body height was measured with a
calibrated stadiometer. The mean of three measurements was
recorded for each variable. Fat mass (FM) and fat-free mass
(FFM) were assessed by multi frequency bio-impedance
(QuadScan 4000; Bodystat, Isle of Man, British Isles).
Resting energy expenditure (REE) was measured by
indirect calorimetry using open circuit ventilated hood
systems, as routinely performed in each centre, and a
standardized validation programme was used to facilitate
pooling of the results from the different centres. REE was
calculated according to the equation of Weir.26 Fat oxidation
(FatOx) was calculated according to the equations of Frayn.27
At the second clinical investigation day indirect calorimetry
measurements on some of or all participants completing the
intervention were carried out in six of eight centres (Sweden,
UK, Czech Republic, France (both centres) and Spain).
After participants rested supine for 15min, venous blood
samples were drawn to determine fasting plasma glucose and
fasting plasma insulin. Plasma glucose concentrations (ABX
diagnostics, Montpellier, France) were measured on a COBAS
MIRA automated spectro-photometric analyzer (Roche diag-
nostica, Basel, Switzerland). Plasma insulin concentrations
were measured with a double antibody radio-immunoassay
(Insulin RIA 100, Kabi-Pharmacia, Uppsala, Sweden).
Homeostasis model assessment (HOMA)28 was used to
estimate insulin release (HOMA-b) and a surrogate measure
of whole-body insulin resistance (HOMA-IR).28–30
Genotyping
Samples of buffy coat were sent on dry ice to the Steno
Diabetes Center in Copenhagen, where DNA was extracted.
Extracted DNA samples were diluted in Tris/EDTA buffer to a
stock DNA solution of 100ng ml1 and a working DNA
solution of 10ngml1. Stock solutions were stored at 80 1C,
working solutions were stored at 4 1C. DNA samples were
stored and handled in locations free of contaminating
polymerase chain reaction products.
High-throughput genotyping of the FTO rs9939609 SNP
was performed using Taqman allelic discrimination
(KBioScience, Herts, UK). DNA samples were available for
764 individuals. There was a 96.9% genotyping success rate
(n¼734) and the genotyping error rate was 0.27%.
Statistical modelling
Examination of Hardy–Weinberg equilibrium was carried out
while taking into account centre differences by summing up
Pearson’s w2 statistics for each centre and comparing with a
w2 distribution with 8 degrees of freedom.
First, general genetic models with no assumption of a
specific effect of the risk allele (A) in individuals hetero-
zygous and homozygous for the A allele compared with
non-carriers (null hypothesis) were analysed. The results
from these analyses were then used to decide whether to
proceed with analyzing models assuming a particular effect
of the risk allele (A) compared with the major allele T:
dominant effect (TT¼0, AT and AA¼1), co-dominant effect
(assessed as an additive effect: TT¼0, AT¼1, AA¼2), or
recessive effect of A allele (TT¼0, AT¼0, AA¼1). Regression
models examining interaction between genotype and diet
were made and if no interaction was found models examin-
ing the main effects of rs9939609 were made.
Change (D) in body weight in kg, DFM (kg), DFFM (kg),
DWC (cm), DHOMA-b, DHOMA-IR, DREE (kcal/24h) and
DFatOx (%) were calculated by subtracting measurement
recorded immediately before randomization from the mea-
surement recorded at the completion of the intervention.
The effects (with 95% confidence intervals (95% CIs)) of
rs9939609 genotype (TT, AT or AA) combined with the
assigned hypo-energetic diet (HF or LF) on Dweight, DFM,
DFFM, DWC, DHOMA-b, DHOMA-IR, DREE and DFatOx were
estimated by separate linear regression models for each
outcome variable. Drop out was similarly analysed by logistic
regression models and additionally by time-to-event analysis.
In models for changes in phenotypes we controlled for
respective baseline values (linear; separate effect of weight,
WC, FM and FFM for men and women; FM, HOMA-b, and
HOMA-IR were log transformed), age (linear in models of
DFFM, DHOMA-b, DHOMA-IR, DREE and DFatOx; linear and
squared in models of Dweight, DFM and DWC), sex and
centre (Gaussian random effect). Models for DREE were
additionally adjusted for baseline FFM and DFFM. Odds ratios
(OR) and hazard ratios (HR) of drop out according to
genotype and randomized diet combined was analysed
adjusting for baseline BMI (linear), age (linear), sex and
centre.
Assessment of main effects was conducted by including
the genotypes as covariates and as a separate covariate the
diet group to which the participants had been randomized.
Gene–diet interaction analyses were carried out by estimating
the genotype-specific difference in mean Dweight, DFM,
DFFM, DWC, DHOMA-b, DHOMA-IR, DREE and DFatOx,
respectivelyFadjusted as described aboveFbetween LF and
the HF. This allowed a comparison of the differences in mean
Dweight, DFM, DFFM, DWC, DHOMA-b, DHOMA-IR, DREE
and DFatOx, respectively for AT and/or AA with TT or TT and
AT depending on an assumed genetic model.
The statistical software STATA version 9.0 (Stata, College
Station, TX, USA), was used for all statistical analyses.
Results
FTO rs9939609 was genotyped successfully in 734 of the 771
obese individuals randomized to one of the two diets. The
rs9939609 allele frequencies were in Hardy–Weinberg equili-
brium (P¼ 0.97).
In randomizing participants to the two hypo-energetic
diets FTO rs9939609 genotype was not distributed evenly
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(P¼ 0.027) between HF and LF diet. Individuals with TT
genotype were more likely to have been randomized to HF
(55.2%) than LF diet (44.8%), heterozygous individuals (AT)
were distributed evenly between the two diets and indivi-
duals homozygous for the risk allele (AA) were more likely to
have been randomized to LF (59.2%) than to HF diet
(40.8%).
In total 115 of the successfully genotyped individuals
failed to complete the 10-week weight loss intervention.
Table 1 presents drop out according to genotype and diet. In
TT drop-out percentage was higher for those randomized to
LF (21.4%) than for those randomized to HF diet (14.6%). For
carriers of the variant A allele drop out percentage was higher
on HF (AT: 17.8%; AA: 28.3%) than LF diet (AT: 6.7%; AA:
16.9%). Adjusting for baseline BMI, age, sex and centre, we
found a significant interaction between FTO rs9939609
genotype and hypo-energetic diet (P for interaction¼0.020)
on odds for drop out (Figure 1) and in a dominant model
odds for drop out was higher on the HF diet than on the LF
diet (P¼0.0030) for A allele carriers. When analysing
without assuming a genetic model the difference was
significant for the AT genotype (P¼0.0022), but not for
the AA genotype alone (P¼0.26). Time-to-event analyses of
drop out gave similar results (not shown, can be obtained
from the corresponding author on request).
Mean values for anthropometrics and metabolic variables
at baseline and mean change during intervention are
presented in Table 2 according to genotype and diet. Among
individuals who completed the intervention and for whom
FTO rs9939609 was genotyped we found no effect of FTO
rs9939609 genotype on Dweight, DFM, DFFM, DWC or
DFatOx (Table 2). Mean Dweight among successfully geno-
typed participants completing the intervention was 6.80 kg
consisting of 5.35 kg DFM and 1.47 kg DFFM. WC
decreased on average by 6.33 cm, whereas FatOx increased
by a 2.5 percentage points from 46.6 to 49.1% of REE.
We found significant interactions between genotype (AT
and AA vs TT) and diet in relation to DREE (P¼0.0055;
n¼387). The combined effects of genotype and diet on DREE
are presented in Figure 2a. Mean DREE was 114 kcal/24h.
For individuals with TT genotype decrease in REE was
75 kcal/24h smaller (P¼0.006) for individuals randomized
to the LF than HF diet. The decrease in REE was 74 kcal/24h
smaller (P¼0.003) for TT genotype on LF than AT/AA on LF.
For AT/AA genotype there was no significant difference in
DREE between LF and HF diet (P¼0.33).
We also found interaction between genotype (AT and AA
vs TT) and diet for DHOMA-b (P¼0.0083; n¼612) and
DHOMA-IR (P¼0.047; n¼612). The combined effects of
genotype and diet on DHOMA-b and DHOMA-IR are
presented in Figures 2b and c. Mean DHOMA-b was 9.22.
For individuals with TT genotype decrease in HOMA-b was
19 units greater (P¼0.006) for individuals randomized to an
LF than a HF diet. The decrease in HOMA-b was 18 units
greater (P¼0.004) for TT genotype on LF than AT/AA
genotype on LF. For AT/AA genotype there was no difference
in DHOMA-b between LF and HF diet (P¼0.47). Mean
DHOMA-IR was 0.34. For TT there was a tendency to a
greater decrease in HOMA-IR on LF than HF diet (0.30 units,
P¼0.14). Decrease in HOMA-IR was 0.44 units greater
(P¼0.013) for TT genotype on LF than AT/AA genotype on
LF. There was no difference in DHOMA-IR between LF and HF
diet for AT/AA (P¼0.17). Additional adjustment for change
in BMI did not change the combined effects of genotype and
diet on either DHOMA-b or DHOMA-IR.
Discussion
In this weight loss intervention study drop out was
statistically related to FTO rs9939609 genotype and macro-
nutrient content of the hypo-energetic diet (HF vs LF).
Among A allele carriers the risk of drop out was higher when
randomized to HF diet than when randomized to LF diet. For
individuals completing the intervention we found no effects
of FTO rs9939609 genotype on Dweight, DFM, DFFM, DWC
Table 1 Drop out percentage according to FTO rs9939609 genotype and
dieta in a randomized 10-week, parallel two arm intervention study
Diet All (%) FTO rs9939609 genotype
TT n¼249 AT n¼ 354 AA n¼ 130
Low-fat, high-CHO 13.3 21.4% 6.7% 16.9%
High-fat, low-CHO 18.1 14.6% 17.8% 28.3%
Both diets 17.7% 12.2% 21.5%
aRandomized to a low-fat, high carbohydrate (CHO), hypo-energetic diet or a
high-fat, low-CHO, hypo-energetic diet in a 10week, parallel two arm
intervention study.
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Figure 1 Combined effects of FTO rs9939609 genotype and fat and
carbohydrate (CHO) content of hypo-energetic diet on drop out from
10-week weight loss intervention with 95% CI for comparison with TT
genotype on low-fat, high-CHO diet (LF). Odds ratios (OR) are from logistic
regression adjusting for baseline body mass index (linear), age (linear), sex
and centre. No assumption of genetic model.
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Table 2 Phenotype baseline valuesa and changesb during interventionc according to genotype at FTO rs9939609 and type of dietd, mean (s.d.)
Genotype at rs9939609 TT AT AA Pe main effect
of rs9939609
Pe gene–diet
interaction
Diet Low-fat,
high-CHO
(n¼88)
High-fat,
low-CHO
(n¼117)
Low-fat,
high-CHO
(n¼168)
High-fat,
low-CHO
(n¼143)
Low-fat,
high-CHO
(n¼64)
High-fat,
low-CHO
(n¼38)
Body mass index, kgm2
Baseline 35.1 (5.2) 35.6 (4.1) 35.7 (4.9) 35.6 (4.9) 35.4 (4.5) 35.1 (4.6)
Change 2.4 (1.2) 2.3 (1.2) 2.4 (1.1) 2.4 (1.2) 2.6 (1.2) 2.2 (1.2)
Body weight, kg
Baseline 97.6 (16.3) 100.3 (13.3) 101.7 (18.0) 100.0 (15.4) 100.1 (15.7) 100.7 (16.1)
Change 6.7 (3.4) 6.6 (3.5) 6.9 (3.4) 6.8 (3.3) 7.4 (3.4) 6.3 (3.8) 0.91 0.55
Fat-free mass, kg
Baseline 58.8 (11.2) 59.0 (10.5) 60.0 (12.5) 59.3 (11.4) 59.7 (11.1) 59.4 (11.1)
Change 1.8 (2.2) 1.4 (2.5) 1.3 (2.6) 1.6 (2.2) 1.7 (1.7) 1.1 (2.4) 0.63 0.095
Fat mass, kg
Baseline 39.0 (12.4) 41.4 (9.4) 41.8 (12.0) 41.1 (11.7) 40.4 (11.3) 41.3 (11.0)
Change 5.0 (3.2) 5.3 (3.2) 5.6 (3.4) 5.3 (3.0) 5.6 (2.8) 5.3 (3.3) 0.63 0.69
Waist circumference, cm
Baseline 104 (12.6) 105 (11.1) 107 (13.5) 105 (12.8) 106 (13.5) 107 (12.5)
Change 6.4 (4.3) 5.7 (4.2) 6.5 (4.6) 6.3 (4.7) 7.1 (4.7) 6.3 (4.2) 0.56 0.74
Fasting plasma glucose, mM
Baseline 5.2 (0.5) 5.5 (0.9) 5.5 (1.4) 5.4 (0.5) 5.3 (0.5) 5.3 (0.6)
Change 0.1 (0.4) 0.2 (0.5) 0.1 (0.6) 0.1 (0.4) 0.1 (0.4) 0.1 (0.4)
Fasting serum insulin, mUml1
Baseline 9.7 (5.4) 10.6 (6.6) 9.9 (6.0) 10.5 (6.3) 9.7 (5.6) 10.7 (7.7)
Change 2.4 (4.6) 1.1 (5.2) 0.6 (5.3) 1.5 (5.8) 0.8 (4.7) 1.2 (5.1)
Insulin release, HOMA
Baseline 115 (64.4) 110 (65.2) 110 (64.1) 115 (59.1) 112 (66.8) 117 (89.5)
Change 25.6 (56.2) 2.4 (55.8) 6.2 (51.5) 11.6 (52.6) 1.1 (64.3) 11.0 (54.7) 0.15f 0.0083*,f
Insulin resistance, HOMA
Baseline 2.3 (1.4) 2.7 (2.0) 2.5 (2.1) 2.5 (1.7) 2.3 (1.4) 2.6 (1.9)
Change 0.6 (1.1) 0.3 (1.4) 0.1 (1.8) 0.4 (1.6) 0.3 (1.2) 0.4 (1.4) 0.13f 0.047*,f
Resting energy expenditure,g kcal/24 h
Baseline 1808 (333) 1894 (307) 1918 (341) 1845 (282) 1876 (267) 1835 (260)
Change 43 (139) 138 (185) 134 (179) 108 (170) 123 (162) 97 (164) 0.19h 0.0055*,h
Fasting fat oxidation,g kcal/24 h
Baseline 867 (335) 894 (382) 903 (376) 877 (325) 870 (427) 780 (387)
Change 35 (372) 5 (355) 67 (433) 20 (353) 1 (356) 81 (336)
Fasting fat oxidation,g %REE
Baseline 47.7 (15.7) 46.9 (17.1) 46.3 (15.4) 47.6 (15.7) 45.7 (21.5) 41.9 (18.4)
Change 3.7 (20.9) 4.0 (17.2) 0.29 (22.6) 2.0 (16.8) 3.7 (18.9) 7.2 (19.3) 0.20 0.31
aFor individuals who completed the intervention. bValue at week 10 minus baseline value. c10-week randomized intervention. dHigh-fat, low-carbohydrate (CHO)
(HF) or low-fat, high-CHO (LF), hypo-energetic diet (600 kcal d1). eStatistical analyses were carried out for the variables relevant to the objective of the study.
P-values from linear regressions adjusting for baseline weight (linear; separate effect for men and women), fat-free mass (FFM) (linear; separate effect for men and
women), fat mass (FM) (log-transformed; linear; separate effect for men and women), waist circumference (WC) (linear; separate effect for men and women), and fat
oxidation (FatOx) (linear) respectively along with age (linear in models of DFFM, and DFatOx; linear and squared in models of Dweight, DFM and DWC), sex and
centre (Gaussian random effect). No assumption of genetic model. fFrom linear regressions adjusting for baseline HOMA-b (logarithm transformed; linear) and
HOMA-IR (logarithm transformed; linear), respectively along with age (linear), sex and centre (Gaussian random effect). Genetic model: dominant. gAfter the
intervention resting energy expenditure (REE) and fat oxidation was measured in B2/3 of the individuals who completed the intervention. (TT, LF: n¼ 48; TT, HF:
n¼85; AT, LF: n¼104; AT, HF: n¼ 85; AA, LF: n¼43; AA, HF: n¼22). hFrom linear regressions adjusting for baseline REE (linear), baseline FFM, change in FFM, age
(linear), sex and centre (Gaussian random effect). *Genetic model: dominant.
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or DFatOx, but we found statistically significant interactions
between FTO rs9939609 genotype and fat and carbohydrate
(CHO) content of the hypo-energetic diet in relation to a
change in three (DREE, DHOMA-b and DHOMA-IR) of eight
investigated obesity-related phenotypes.
In the original analyses of the NUGENOB weight loss
intervention not including genotypes a greater drop out was
seen among participants randomized to HF than LF diet.24
Although there was only a significant difference in the risk of
drop out between diets for AT genotype (greater on HF than
LF) there was also a trend towards a greater drop out on HF
diet than LF diet for AA genotype. It would seem more
plausible to see an effect in all carriers of the A allele rather
than just in heterozygous individuals, but clearly more AA
individuals would need to be studied to confirm this. The
reason for differences in drop out rates according to the
genotype is unclear, but could potentially be explained by
preferences for dietary fat vs CHO or metabolic effects. A
study by Cecil et al.15 found the FTO rs9939609 A-allele
associated with increased energy intake in children. Intake of
all macronutrients tended to be greater in A-allele carriers
but especially so for fat intake. In addition, the few studies
that examined the relationship between appetite14 and
dietary intakes16,31 with FTO, were performed in children
or adolescents. In this context, an understanding of the
interactions between macronutrient intake or dietary com-
ponents and the genotype is important to provide a basis for
determining the role of dietary intake and habits in the
prevalence and pathogenesis of important conditions such
as type 2 diabetes and obesity.32
Two previous studies have examined FTO variants in
relation to weight loss interventions.21,22 Unfortunately,
drop out from the interventions was not analysed in either of
these reports. Our finding of no main effects of FTO
rs9939609 on change in anthropometrics and metabolic
estimates during intervention is in agreement with the two
studies.21,22
Other studies than the present are suggestive of modifiable
effects of FTO variants.5,33 Unfortunately, it was not possible
to examine the interaction between genotype and fat and
CHO content in either of the two previous studies of FTO
variants and response to weight loss intervention. In the first
study all individuals were allocated to the same lifestyle
intervention and in the second study all individuals were
given the same dietary recommendations of reduced fat and
sugar intake.
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Figure 2 Combined effects of FTO rs9939609 genotype and fat and
carbohydrate (CHO) content of hypo-energetic diet on change in (a) resting
energy expenditure (DREE), (b) insulin release (DHOMA-b) and (c) insulin
resistance (DHOMA-IR) with 95% CI for comparison with TT genotype on low-
fat, high-CHO diet (LF). Estimates of effect of genotype and diet on DREE,
DHOMA-b and DHOMA-IR from linear regressions adjusting for baseline REE
(linear), HOMA-b (logarithm transformed; linear) and HOMA-IR (logarithm
transformed; linear) respectively along with age (linear), sex and centre
(Gaussian random effect). Model for DREE additionally adjusted for baseline
fat-free mass (FFM) and DFFM. Genetic model: dominant.
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Previous studies suggest that FTO variants associated with
obesity are not associated with resting energy expendi-
ture.15–17 However, in this study we found an interaction
between rs9939609 genotype and the dietary fat and CHO
content in DREE. The difference in DREE between LF and HF
diet in TT subjects of 75 kcal/24h may seem small consider-
ing baseline values of REE at 1800–1900 kcal/24h. It is
however a difference in DREE of more than 50%. It can be
speculated that the greater decrease in REE on a HF than LF
diet for TT genotype may expose these individuals to a
higher tendency to weight regain, which we unfortunately
have no data on.
The FTO rs9939609 risk A-allele may be associated with
lower whole-body insulin sensitivity. A study in 6000 Danes
found that insulin sensitivity was significantly decreased in
homozygous carriers and that the impact of the FTO
rs9939609 genotype on BMI levels was highly influenced
by insulin sensitivity.5 In the present study we found an
interaction between rs9939609 genotype and the dietary fat
and CHO content in DHOMA-b and DHOMA-IR.
Given the strong association between FTO variants and
obesity it may come as a surprise that we did not find an
effect of rs9939609 on either Dweight, DWC, DFM or DFFM
during a weight loss dieting period. One possible explana-
tion could be that FTO variants primarily influence body
fatness early in life and that effect persists into adulthood.
The effect of FTO variants on body composition and on the
risk of obesity and overweight is observed already in
childhood to the same level as seen in adolescence and later
in adulthood.1,34,35 Although no association is observed with
birth weight or with the ponderal index at birth,1,35,36
already at the age of 2 weeks FTO SNPs are associated with
increased weight and ponderal index.36 Another possible
explanation for the lack of association between rs9939609
and Dweight, DWC, DFM and/or DFFM is that weight loss,
which mainly is reducing the amount of fat in the
adipocytes, from a metabolical and biological point of view,
is not the reverse of primary weight gain, which also implies
adipogenesis.
Analysing the allocated diet (HF or LF) rather than actual
diet may have obscured the associations examined in this
study. Although average weight loss was as expected
indicating that participants on average complied with the
600 kcal day1 energy deficit the inter-individual variation in
weight loss suggests that not all individuals complied fully
with the energy restrictionFsome individuals had a higher
energy intake and others a lower energy intake than
targeted.24 Similarly, for compliance with fat and CHO
content of HF and LF diet; the differences in changes in
blood lipids between diets were as expected, but there were
considerable inter-individual differences in reported fat and
CHO composition within both diets.23 However, using
reported intake has its own problems with potential
misreporting and would challenge the advantage of the
study’s randomized design. As it is seen for FTO rs9939609
genotype in this study randomization is no guarantee for
even distribution of potential risk factors between study
groups. On the other hand uneven distribution of one risk
factor between the two diet groups does not imply that
unknown and unmeasured risk factors in general are
distributed unevenly. As the multiple statistical testing done
in this study is not analogous to repeated testing of the same
null hypothesis multiple times and as the choice of
analysing FTO is clearly hypothesis-driven the analyses are
not adjusted for multiple testing. However, false-positive
results cannot be excluded and the results obviously need
replication in other studies.
Previous analyses comparing the two diets in the
NUGENOB study but not including genetic factors led to
the conclusion that the LF and HF hypo-energetic diet
produced similar mean weight loss and that both diets
produced favourable changes in circulating levels of fasting
blood lipids, insulin and glucose.24 Although we found no
effect of FTO rs9939609 on weight loss, neither on its own
nor in combination with the fat and CHO content of the
hypo-energetic diet, the results in the present study suggest
that for healthy obese carriers of the FTO rs9939609 risk
A-allele the risk of dropping out from the intervention is
lower on LF than HF hypo-energetic diet. For non-carriers
completing the intervention the decrease in REE was smaller,
and the decrease in HOMA-b and HOMA-IR was greater
on LF than on a HF diet. LF hypo-energetic diet may thus
be preferable to HF hypo-energetic diet for healthy obese
wishing to lose weight irrespective of FTO rs9939609
genotype. However, because there have been no previous
reports of similar associations these findings need to be
replicated in a different population and possible mechanism
responsible for these associations should be explored.
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